Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Replimune Group, Inc. (Nasdaq: REPL) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a clinical stage biotechnology issuer. Replimune, founded in 2015 and headquartered in Woburn, Massachusetts, develops HSV‑1‑based oncolytic immunotherapies through its proprietary RPx platform, with lead programs such as RP1 (vusolimogene oderparepvec) and RP2.
Through this page, users can review Replimune’s current reports on Form 8‑K, which frequently highlight material events including FDA interactions, clinical milestones and financial updates. Recent 8‑K filings have described the FDA’s Complete Response Letter for the RP1 BLA in advanced melanoma, completion of a Type A meeting with the agency, acceptance of a BLA resubmission with a defined PDUFA date, quarterly financial results, and outcomes of the company’s annual meeting of stockholders.
In addition to 8‑Ks, investors can reference Replimune’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (accessible via the SEC’s EDGAR system) for detailed information on the company’s clinical programs, risk factors, financial condition and cash runway assumptions. The DEF 14A proxy statement provides insight into governance, board structure, executive compensation and matters submitted to shareholder vote, such as director elections and incentive plan amendments.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, helping users quickly understand topics like trial design disclosures, regulatory status updates for RP1 and RP2, and the implications of shareholder meeting results. Real‑time updates from EDGAR mean that new Replimune filings, including future 10‑K, 10‑Q, 8‑K and proxy materials, are made available promptly.
For those monitoring insider and equity‑related activity, Replimune’s filings also describe equity incentive plans and inducement grants under Nasdaq Listing Rule 5635(c)(4). Form 4 insider transaction reports, when filed, can be viewed alongside these materials to provide additional context on equity ownership and changes over time.
Replimune Group reported a larger net loss as it continues investing heavily in its oncolytic immunotherapy pipeline. For the nine months ended December 31, 2025, the company recorded a net loss of $240.7 million, compared with $173.2 million a year earlier, driven mainly by higher research and development and selling, general and administrative expenses.
Cash and cash equivalents were $122.9 million and short‑term investments were $146.2 million as of December 31, 2025, and management believes this liquidity can fund operations for at least 12 months, including potential RP1 commercialization. The balance sheet also shows $47.6 million of long‑term debt with Hercules Capital and total lease liabilities of $28.7 million.
Clinically, the FDA issued a complete response letter for the RP1 BLA in advanced melanoma in July 2025, but later accepted a resubmitted BLA with a new PDUFA date of April 10, 2026. Replimune is running the Phase 3 IGNYTE‑3 confirmatory trial in anti‑PD‑1 failed melanoma and the REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma.
The company also faces a putative securities class action, related shareholder derivative suits, a shareholder demand letter, and an SEC investigation focused on the RP1 BLA; Replimune denies wrongdoing and is cooperating with regulators.
Replimune Group, Inc. amended its Loan and Security Agreement with Hercules Capital and other lenders, extending a key revenue milestone date to September 30, 2027 and modifying several loan tranches. As part of this Third Amendment, the third loan tranche was increased to $35 million and fully funded on January 29, 2026.
The amendment adjusts future borrowing capacity and timing, including changes to the sizes and availability windows of the fourth, fifth, and sixth tranches, and sets the interest rate to the greater of 8.50% or the Prime Rate plus 1.75%. The loan amortization start date was pushed back from October 1, 2026 to October 1, 2027. The company also furnished a news release with financial results for the quarter ended December 31, 2025 as an exhibit.
Replimune Group, Inc. reported that it has released an updated corporate presentation covering recent business and strategic developments and clinical data for its RP1 and RP2 programs. The company plans to use this presentation in meetings with analysts, investors and others, including at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The slide deck is furnished as Exhibit 99.1, and a replay of the J.P. Morgan presentation webcast will be available on the company’s website under “Investors and Media” for 30 days. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference into other filings unless specifically stated.
Replimune Group, Inc. director reported an option exercise and share sale on 12/09/2025. The director exercised a stock option for 3,169 shares of common stock at an exercise price of
The disclosure explains that the option was exercised due to the upcoming 01/21/2026 expiration date, and that all 3,169 shares underlying this stock option had vested on 01/21/2016.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Commercial Officer, who filed a Form 4 as a single reporting person. On 11/17/2025, the officer sold 5,208 shares of Replimune common stock in a transaction coded "S" for sale. The sale was executed at a broker-calculated weighted average price of $9.10 per share, with individual trades ranging from $8.88 to $9.26 per share.
The shares were sold solely to cover tax withholding obligations arising from the partial vesting of the officer’s restricted stock units under an irrevocable "sell to cover" provision, and are described as non-discretionary. Following this transaction, the officer beneficially owns 123,088 shares of Replimune common stock in direct ownership.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 7,248 shares of common stock in a transaction coded "S" at a weighted average price of $9.10 per share. The company explains this was an automatic sale to cover tax withholding obligations tied to the partial vesting of previously granted Restricted Stock Units under an irrevocable "sell to cover" provision, rather than a discretionary sale.
After this transaction, the officer beneficially owns 139,685 shares of Replimune common stock in direct ownership. The shares were sold as part of a block trade in multiple transactions at prices ranging from $8.88 to $9.26 per share, with detailed pricing information available on request.
Replimune Group, Inc. filed Amendment No. 1 to a shelf registration statement, covering the potential offering of up to $250,000,000 of common stock, preferred stock, debt securities, warrants, and units, to be sold from time to time. The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock under a Sales Agreement with Leerink Partners LLC, which is included within the $250,000,000 aggregate. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The company states it may use net proceeds to fund continued development of its RPx platform, including indication expansion with RP1 in skin cancer and broadening RP2 development, and for general corporate purposes. Any unsold portion of the $100,000,000 ATM may be offered under the base shelf via prospectus supplement. Replimune’s common stock trades on Nasdaq as REPL; the last reported sale price was $8.58 on November 5, 2025.
Replimune Group, Inc. furnished a current report describing that it issued a news release with its financial results for the second fiscal quarter ended September 30, 2025 and certain corporate updates. The news release is attached as Exhibit 99.1. The company clarifies that this earnings information, including Exhibit 99.1, is being furnished under the securities laws rather than filed, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Replimune Group (REPL) filed its quarterly report, highlighting increased R&D investment and a larger net loss as it advances lead therapy RP1. For the quarter ended September 30, 2025, operating expenses were $84.3 million (R&D $57.9 million; SG&A $26.4 million), resulting in a net loss of $83.1 million, or $0.90 per share. Cash and cash equivalents were $102.3 million and short‑term investments were $221.3 million.
Total assets were $389.5 million and stockholders’ equity was $263.3 million. Net cash used in operating activities for the six months was $158.2 million, offset by $149.2 million provided by investing activities, ending with $104.0 million in cash, cash equivalents and restricted cash. Long‑term debt, net, was $47.2 million under the Hercules facility. The company stated its cash, cash equivalents and short‑term investments are expected to fund operations for at least 12 months from issuance of the statements. The FDA accepted the resubmission of the BLA for RP1 in combination with nivolumab in advanced melanoma, with a PDUFA date of April 10, 2026.
Replimune Group, Inc. (REPL) announced a key regulatory milestone. The FDA accepted the company’s resubmission of its Biologics License Application for RP1 in combination with nivolumab to treat patients with advanced melanoma. The FDA set a PDUFA date of April 10, 2026 based on a Class II resubmission timeline.
The acceptance confirms the application is filed for review and establishes a clear decision date. Replimune furnished a related news release as Exhibit 99.1. Outcomes will depend on the FDA’s review of the RP1 plus nivolumab data package.
FAQ
What is the current stock price of Replimune Group (REPL)?
What is the market cap of Replimune Group (REPL)?
